Combination of First Generation Proteasome Inhibitor Bortezomib with Temozolomide and Radiotherapy in Glioblastoma 2D and 3D Cell Cultures

Proceedings

Unal, Semra¹  Atasoy, Beste Melek²  Gokce, Tilbe³  Gunduz, Oguzhan⁴  Arslan, Sema⁵ 

[1] Advanced Nanomaterials Research Laboratory, Marmara University, 34854 Ä°stanbul, Turkey;Author to whom correspondence should be addressed.;Department of Radiation Oncology, School of Medicine, Marmara University, 34854 Ä°stanbul, Turkey;Presented at the 2nd International Cell Death Research Congress, Izmir, Turkey, 1–4 November 2018;School of Medicine/Genetic and Metabolic Diseases Research and Investigation Center, Marmara University, 34854 Ä°stanbul, Turkey

关键词: glioblastoma;    bortezomib;    temozolomide;    radiotherapy;    3D-culture;   

DOI  :  10.3390/proceedings2251579

学科分类：社会科学、人文和艺术（综合）

来源: mdpi

【 摘 要 】

Glioblastoma is the most common high-grade brain tumor in adults, which has a rapidly developing radiotherapy/chemotherapy resistance and high recurrence rate. The aim of our study is to determine the effects of bortezomib that is a quite important proteasome inhibitor on glioblastoma tumors in the 3D environment. In this study, we have performed bortezomib and temozolomide drug treatments and radiation applications to U251 cell line in 2D and 3D cultures with PCL/gelatin/graphene nanofibrous scaffolds. The best result was reached in the combination of drugs with radiation therapy that has the most decreased viability in the experiment group.

【 授权许可】

CC BY